Insulin Detemir: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Insulin Detemir. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Study e | 83.7% |
| Study f | 82.3% |
| Study c | 76.5% |
| Nph | 76.4% |
| Study a | 75.1% |
| Study d pediatric | 2.677% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
LEVEMIR is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long acting) insulin for the control of hyperglycemia.
Source: FDA labeling via NIH DailyMed (set 2b8d9730…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.